CTOs on the Move

Keune Haircosmetics

www.keune.com

 
Keune Haircosmetics is a Lawrenceville, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.keune.com
  • 1440 Lakes Pkwy Ste 500
    Lawrenceville, GA USA 30043
  • Phone: 678.377.5226

Executives

Name Title Contact Details

Similar Companies

Medical Asset Management Inc

Medical Asset Management Inc is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

John P Robarts Research Institute

John P Robarts Research Institute is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genalyte

Since 2007, Genalyte has been guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes. We launched our first instrument in 2012 in the pharmaceutical industry and academia for a range of healthcare applications including autoimmune disease monitoring, screening of cancer biomarkers, testing for infectious agents and detecting anti-drug antibodies. By reducing tests to a microscopic size in a highly multiplex environment on the surface of silicon chips we are able to generate more information from a smaller sample in less time than conventional techniques.

Village on Lee Retirement Center

Village on Lee Retirement Center is a Lawton, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cleveland Biolabs

Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.